Interestingly, blocking the SRC/EGFR-dependent ITGB4/FAK pathway, which subsequently inactivates the Akt and p38/MAPK pathways contributes to the suppression of migration and invasiveness of breast cancer cells and reversal of EMT process after treatment with Ziyu II [31]. The gene discussed is ITGB4; the disease is breast carcinoma.